Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Slides:

Advertisements

Similar presentations

Prevention of graft-versus-host disease by anti–IL-7Rα antibody by Brile Chung, Eric P. Dudl, Dullei Min, Lora Barsky, Nancy Smiley, and Kenneth I. Weinberg.

Advertisements

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation Qing Ma, Dan Li, Roza Nurieva, Rebecca.

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:

Expression of Chemokines in GVHD Target Organs Is Influenced by Conditioning and Genetic Factors and Amplified by GVHR Markus Y. Mapara, Corinna Leng,

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease Robert Zeiser,

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver Alina Schreder,

Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.

by Yoshinobu Maeda, Pavan Reddy, Kathleen P

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.

Mesenchymal Stem Cells (MSCs) Attenuate Cutaneous Sclerodermatous Graft-Versus- Host Disease (Scl-GVHD) through Inhibition of Immune Cell Infiltration.

IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome Gerhard C. Hildebrandt, Krystyna.

PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model) Yehudith Azar, Reut.

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Lucrezia Colonna, Mareike.

by Oleg I. Krijanovski, Geoffrey R. Hill, Kenneth R

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality Kai Sun,

Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice Chien-Chun Steven Pai,

Evelyn C. Nieves, Tomomi Toubai, Daniel C

Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal Patricia A. Taylor,

Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across.

Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT Alwi M. Shatry, Derry C. Roopenian, Robert B.

Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels Chien-Chun Steven.

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.

T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice Denis R. Burger, Yvonne Parker, Kathryn.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease Haruko Sugiyama,

A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning Gabor Varadi,

Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.

Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease Xiao Chen, Rupali Das, Richard Komorowski,

The Innate Immune Sensor Sting Can Augment or Ameliorate Graft-Versus-Host Disease Dependent on the Genetic Disparity between Donors and Recipients Cameron.

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Christian Scheffold, Yolanda C. Scheffold,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects Jeffrey S. Moyer, Gabriel.

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either.

Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G

Specific donor Vβ-associated CD4+ T-cell responses correlate with severe acute graft- versus-host disease directed to multiple minor histocompatibility.

Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect Shawn G Clouthier,

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution Maria Gendelman, Maryam Yassai,

Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease Wonyoung Kim, Juyang.

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Presentation transcript:

Importance of Interleukin-7 in the Development of Experimental Graft-Versus-Host Disease Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg Biology of Blood and Marrow Transplantation Volume 14, Issue 1, Pages 16-27 (January 2008) DOI: 10.1016/j.bbmt.2007.07.015 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Treatment with IL-7 increased GVHD-related mortality in B6.IL-7-/- recipient animals after allogeneic LN BMT. The B6 or B6.IL-7-/- recipients that had received 1300 cGy TBI received either 1 × 106 TCD BM and 4 × 106 LN cells from BALB/c donor mice, or similar cell numbers of LN and BM cells from congenic B6.SJL donors (CD45.1), and were then treated with recombinant human IL-7 (500 ng twice a day via subcutaneous injection) for 60 days. Survival over the 150 days after BMT is shown. Survival of all wild-type allogeneic B6 recipients was significantly lower than that of the congenic recipients (∗P < .002). Survival of the PBS-treated B6.IL-7-/- allogeneic recipients was significantly lower than that of congenic B6.IL-7-/- recipients (∗P < .03). The difference between the IL-7– and PBS-treated allogeneic B6.IL-7-/- recipients is significant (∗P < .002). Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Treatment with IL-7 increased GVHD-related morbidity after allogeneic BMT. The severity of GVHD was determined by GVHD clinical grading system with scoring for 5 clinical criteria: percentage of weight loss, skin integrity, posture, mobility, and fur texture [31]. Clinical signs were graded on a scale of 0 to 2, (0, absent; 1, moderate; 2, severe), and the individual signs were summed. Shown are GVHD clinical index scores at 4 and 6 weeks for B6 recipients (A) and B6.IL-7-/- recipients (B). Differences between the IL-7–treated and PBS-treated allogeneic recipients are P < .05 in both B6 recipients and B6.IL-7-/- recipients (∗). Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Histological evidence of an increase in GVHD as a result of IL-7 administration. Skin and small intestine tissues from the recipients were analyzed at day 30 after BMT. Representative tissue samples from each group of mice were stained with hematoxylin and eosin. The tissue sections of skin and small intestine from the PBS-treated and IL-7–treated congenic BMT plus LN recipients and the PBS-treated allogeneic IL-7-/- recipients demonstrated normal histology. The tissue sections from allogeneic wild-type B6 recipients treated with PBS or IL-7 and allogeneic B6.IL-7-/- recipients treated with IL-7 showed evidence of GVHD, with lymphocytic infiltration and inflammation in the gut sections. Shown are hematoxylin and eosin staining of skin or gut sections from B6 (A) and B6.IL-7-/- (B) recipients of either allogeneic or congenic LN and TCD BM. Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Administration of IL-7 resulted in increased number of donor CD4 and CD8 T cells in blood, LNs, and spleen after allogeneic BMT. Donor-derived peripheral lymphocyte numbers in B6 and B6.IL-7-/- recipients sacrificed 10 or 30 days after allogeneic transplantation with BALB/c LN and TCD BM cells were analyzed. Shown are numbers of donor CD4 and CD8 T cells in peripheral blood (A and B), LN (C and D), and spleen (E and F) of B6 and B6.IL-7-/- recipients at days 10 and 30. ∗Significant differences (P < .05) between the PBS- and IL-7–treated groups. Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Administration of IL-7 resulted in increased number of donor CD4 and CD8 T cells in blood, LNs, and spleen after allogeneic BMT. Donor-derived peripheral lymphocyte numbers in B6 and B6.IL-7-/- recipients sacrificed 10 or 30 days after allogeneic transplantation with BALB/c LN and TCD BM cells were analyzed. Shown are numbers of donor CD4 and CD8 T cells in peripheral blood (A and B), LN (C and D), and spleen (E and F) of B6 and B6.IL-7-/- recipients at days 10 and 30. ∗Significant differences (P < .05) between the PBS- and IL-7–treated groups. Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Progressive disappearance of donor-derived allogeneic T lymphocytes in the absence of IL-7. After allogeneic transplantation with BALB/c LN and TCD BM cells, donor T cells from the peripheral blood of B6.IL-7-/- recipient mice treated with IL-7 or PBS were gated and stained for CD4 and CD8 at days 10 and 30. Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 IL-7 is required for IL-7 administration to maintain activated donor T cells in the LN during allogeneic proliferation at day 10. 1 ×106 TCD BM and 4 × 106 CFSE-labeled LN cells from either congenic or allogeneic donors were transplanted into either lethally irradiated B6 or B6.IL-7-/- recipients. At day 10, most of the proliferating CFSE-labeled congenic (CD45.1+) donor CD4 (A) and CD8 (B) T cells in lymph nodes of the B6 recipients did not express the CD69 activation marker, whereas the allogeneic (H2Kd) donor cells were predominantly CD69+. The frequency of donor-derived CD4 or CD8 T cells in the lymph nodes that expressed CD69 after allogeneic transplantation was not significantly changed by the IL-7 treatment of either B6 (C) or B6.IL-7-/- (D) recipients. (E) IL-7 treatment of the B6.IL-7-/- allogeneic recipients increased the absolute number of activated (CD69+) donor-derived CD4 and CD8 T lymphocytes (∗P < .02 for PBS vs IL-7). Biology of Blood and Marrow Transplantation 2008 14, 16-27DOI: (10.1016/j.bbmt.2007.07.015) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions